We used Western blot analysis to assess the effect of ZA and BPH treatment on protein activation in the RAS-RAF-MEK-ERK and RAS-PI3K-Akt-mTOR pathways (Figure 3B). The gene discussed is MTOR; the disease is benign prostatic hyperplasia.